Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Single-Centre Validation Of a Disease Risk Index For Estimating Survival and Relapse In Allogeneic Hematopoietic Stem Cell Transplant Recipients: Sample Size, Adequate Follow-Up, and Use Of Local Data Are Vital Considerations

Andrew B M Lim, MBBS, FRACP, FRCPA, Andrew W. Roberts, MD, PhD, Kate Mason, RN, Ashish R. Bajel, MBBS, FRACP, FRCPA, Jeffrey Szer, MBBS, David Ritchie, MBBS, PhD, FRACP, FRCPA

Blood (2013) 122 (21): 2143.

https://doi.org/10.1182/blood.V122.21.2143.2143

Published: 2013

Journal Articles

The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well-Tolerated in Patients with Relapsed Non-Hodgkin Lymphoma: Interim Results of a Phase I Study

Matthew S. Davids, MD, Andrew W. Roberts, MD, PhD, Mary Ann Anderson, PhD, John M. Pagel, MD, PhD, Brad S. Kahl, M.D., John F. Gerecitano, MD, PhD, David E. Darden, MS, Cathy E. Nolan, BS, Lori A. Gressick, BS, Jianning Yang, PhD, Brenda J. Chyla, PhD, Todd A. Busman, MS, Alison M. Graham, PhD, Elisa Cerri, MD, Sari H. Enschede, MD, Rod A. Humerickhouse, MD, John F. Seymour, MBBS FRACP

Blood (2012) 120 (21): 304.

https://doi.org/10.1182/blood.V120.21.304.304

Published: 2012

Journal Articles

Results of a Phase 2 Study of Pacritinib (SB1518), a Novel Oral JAK2 Inhibitor, In Patients with Primary, Post-Polycythemia Vera, and Post-Essential Thrombocythemia Myelofibrosis

Rami S. Komrokji, MD, Martha Wadleigh, MD, John F. Seymour, MD, PhD, Andrew W. Roberts, MD, PhD, Luen Bik To, Huan J. Zhu, MD, PhD, Ruben A. Mesa, MD

Blood (2011) 118 (21): 282.

https://doi.org/10.1182/blood.V118.21.282.282

Published: 2011

Journal Articles

Pamidronate Therapy for One Year after Allogeneic Bone Marrow Transplantation (AlloBMT) Reduces Bone Loss from the Lumbar Spine, Femoral Neck and Total Hip.

Andrew C. Grigg, MD, Peter Shuttleworth, RN, John Reynolds, PhD, Jeff Szer, MD, Anthony P. Schwarer, MD, Andrew W. Roberts, MD, Ken F. Bradstock, MD, Chi-Hung Hui, MD, Richard Herrmann, MD, Peter Ebeling, MD

Blood (2004) 104 (11): 2253.

https://doi.org/10.1182/blood.V104.11.2253.2253

Published: 2004

Journal Articles

ENU Mutagenesis Screen Identifies a Novel Regulator of Platelet Production.

William S. Stevenson, MD, Donald Metcalf, MD, Douglas J. Hilton, PhD, Andrew W. Roberts, MD, PhD, Warren S. Alexander, PhD

Blood (2004) 104 (11): 518.

https://doi.org/10.1182/blood.V104.11.518.518

Published: 2004

Journal Articles

Aberrant G-CSF- and IL-6-Induced Proliferation and Differentiation in Suppressor of Cytokine Signaling-3 (SOCS3)-Deficient Progenitor Cells.

Andrew W. Roberts, MD PhD, Ben A. Croker, PhD, Warren Alexander, PhD, Donald Metcalf, MD

Blood (2004) 104 (11): 821.

https://doi.org/10.1182/blood.V104.11.821.821

Published: 2004

NARROW

Single-Centre Validation Of a Disease Risk Index For Estimating Survival and Relapse In Allogeneic Hematopoietic Stem Cell Transplant Recipients: Sample Size, Adequate Follow-Up, and Use Of Local Data Are Vital Considerations

The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well-Tolerated in Patients with Relapsed Non-Hodgkin Lymphoma: Interim Results of a Phase I Study

Results of a Phase 2 Study of Pacritinib (SB1518), a Novel Oral JAK2 Inhibitor, In Patients with Primary, Post-Polycythemia Vera, and Post-Essential Thrombocythemia Myelofibrosis

Pamidronate Therapy for One Year after Allogeneic Bone Marrow Transplantation (AlloBMT) Reduces Bone Loss from the Lumbar Spine, Femoral Neck and Total Hip.

ENU Mutagenesis Screen Identifies a Novel Regulator of Platelet Production.

Aberrant G-CSF- and IL-6-Induced Proliferation and Differentiation in Suppressor of Cytokine Signaling-3 (SOCS3)-Deficient Progenitor Cells.

Email alerts

ASH Publications

American Society of Hematology

Single-Centre Validation Of a Disease Risk Index For Estimating Survival and Relapse In Allogeneic Hematopoietic Stem Cell Transplant Recipients: Sample Size, Adequate Follow-Up, and Use Of Local Data Are Vital Considerations

The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well-Tolerated in Patients with Relapsed Non-Hodgkin Lymphoma: Interim Results of a Phase I Study

Results of a Phase 2 Study of Pacritinib (SB1518), a Novel Oral JAK2 Inhibitor, In Patients with Primary, Post-Polycythemia Vera, and Post-Essential Thrombocythemia Myelofibrosis

Pamidronate Therapy for One Year after Allogeneic Bone Marrow Transplantation (AlloBMT) Reduces Bone Loss from the Lumbar Spine, Femoral Neck and Total Hip.

ENU Mutagenesis Screen Identifies a Novel Regulator of Platelet Production.

Aberrant G-CSF- and IL-6-Induced Proliferation and Differentiation in Suppressor of Cytokine Signaling-3 (SOCS3)-Deficient Progenitor Cells.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only